Member Webinar COVID-19: Monoclonal Antibody (mAb) Treatments Briefing
Monoclonal antibody (mAb) treatments were authorized by the FDA for emergency use in November 2020. Studies show that when administered early in the course of infection, these outpatient infusions are 87% effective in impeding disease progression and preventing hospitalizations. This webinar will brief members on the latest outcomes employing this therapy, and how to access it via public-private partnerships.
Non-Member Price: N/A
Discounted Member Price: $0.00
Your Price: N/A